Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
复制标题
DOI：
10.1002/cncr.29871
复制
发表时间：
2016-04-01
期刊：
影响因子：
6.2
通讯作者：
Willman CL
中科院分区：
文献类型：
--
作者：
Tricoli JV;Blair DG;Anders CK;Bleyer WA;Boardman LA;Khan J;Kummar S;Hayes-Lattin B;Hunger SP;Merchant M;Seibel NL;Thurin M;Willman CL
青少年和年轻成人（AYA）癌症患者在总体生存方面没有达到与年幼儿童或老年人相同的改善。造成这种差异的一个可能原因可能是AYA癌症表现出独特的生物学特性，导致临床和治疗耐药行为的差异。该报告来自NCI和Live Strong Foundation联合主办的题为“青少年和青年肿瘤学的下一步”研讨会的生物学部分，总结了五种AYA癌症的生物学和转化研究进展的现状；结直肠癌（CRC）、乳腺癌、急性淋巴细胞白血病（ALL）、黑色素瘤和肉瘤。本次会议得出的结论包括需要对AYA癌症进行基础生物学、基因组学和模型开发，以及进行转化研究以阐明儿科、AYA和成人癌症之间的任何根本差异。未来研究的生物学问题是，成人和AYA结直肠癌之间是否存在突变或信号通路差异，这些差异可以在临床上用于开发治疗AYA癌症的新疗法和开发伴随诊断。
Adolescent and young adult (AYA) cancer patients have not attained the same improvements in overall survival that either younger children or older adults have. One possible reason for this disparity may be that the AYA cancers exhibit unique biological characteristics resulting in differences in clinical and treatment resistance behaviors. This report from the biological component of the jointly sponsored NCI and Live Strong Foundation workshop entitled Next Steps in Adolescent and Young Adult Oncology” meeting summarizes the current status of biological and translational research progress for five AYA cancers; colorectal cancer (CRC) breast cancer, acute lymphoblastic leukemia (ALL), melanoma and sarcoma. Conclusions from this meeting included the need for basic biological, genomic and model development for AYA cancers, as well as translational research studies to elucidate any fundamental differences between pediatric, AYA and adult cancers. The biological questions for future research are whether there are mutational or signaling pathway differences for example between adult and AYA colorectal cancer that can be clinically exploited to develop novel therapies for treating AYA cancers and to develop companion diagnostics.